- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Banking & Finance
- Energy & Infra
- Case Study
- Web Exclusive
- Property Review
- Digital India
- Work Life Balance
- Test category by sumit
The Rockefeller Foundation awards new grants to scale up COVID-19 testing in India
The Rockefeller Foundation awards new grants to scale up COVID-19 testing in India
Photo Credit :
New York [USA], October 19 (ANI/NewsVoir): To support the expansion of COVID-19 testing and contact tracing across India, The Rockefeller Foundation announced two new grants to The Center for Cellular and Molecular Platforms and PATH.
The grants, totaling $5.5 million, will support domestic manufacturing of critical testing materials and the deployment of scalable testing programs, essential to mitigating the virus' spread.
Additionally, the grants will advance efforts to leverage data and technology to strengthen pandemic surveillance and response. These grants are part of a broader effort to accelerate equitable access to testing technology in India as a key lever to contain the spread of COVID-19 and reduce test positivity rates.
India has recorded significant rises in COVID-19 cases, placing it on track to surpass the U.S. as the country with the highest number of infections. Supply chain shortages for diagnostic tests and insufficient testing capacities in certain parts of the country have negatively impacted its overall pandemic response.
By expanding the domestic production and national self-sufficiency of essential diagnostic technology and implementing scalable testing strategies, India will be better equipped to deploy tools to mitigate the virus' spread, strengthening its COVID-19 response overall.
"Expanding access to COVID-19 testing, especially among high-risk populations, is critical to safeguarding the health of Indians," said Prof. K Vijay Raghavan, Principal Scientific Advisor to the Government of India.
"With support from The Rockefeller Foundation, research institutes will be able to support MSMEs to manufacture high quality, yet low cost molecular diagnostics that meet global standards. These collaborations will not only help to solve a critical domestic challenge, provide for import substitution, but will also enable India to better contribute to the global COVID-19 response," K Vijay Raghavan added.
The Foundation's new grants include:
The Center for Cellular and Molecular Platforms (C-CAMP) is receiving funding to scale up the local manufacturing of reagents and testing solutions in India, providing the country with the elements needed to domestically produce reverse transcription polymerase chain reaction (RT-PCR) testing kits. In coordination with the Bangalore Biotechnology Cluster, C-CAMP will leverage public-private partnerships to develop a roadmap for the production of RT-PCR testing kits and provide data-driven projections, informing a national plan for the production of at least 10 million testing kits per month. By increasing the availability of testing equipment, C-CAMP will contribute to scaling up India's testing capacity as a whole.
"RT-PCR tests remain the gold standard for confirming active COVID-19 infections," said Dr. Taslimarif Saiyed, C-CAMP CEO and Director. "By helping scale up domestic test production, this grant will strengthen India's diagnostic capacities and improve its ability to mitigate the virus."
PATH has received a grant to expand COVID-19 testing capacity in Uttar Pradesh, Maharashtra and Punjab. With this funding, PATH will support state governments to develop and deploy optimized testing strategies that can be replicated and scaled up rapidly, seek to make COVID-19 screening and diagnostic tools available at an affordable cost, create an ecosystem of faster diagnosis of COVID-19 in key geographies, and establish pandemic surveillance models.
"The evolving nature of COVID-19 has highlighted the need for rapidly deployable testing strategies,"said Neeraj Jain, PATH's India Country Director. "
By using this partnership to establish working models, we can help ensure more people have access to testing and provide public health officials with the information they need to keep their communities safe," Neeraj Jain added.
"Scaling up COVID-19 testing provides crucial data insights that can help inform India's response and direct targeted interventions to those most in need," said Dr. Naveen Rao, The Rockefeller Foundation's Senior Vice President, Health.
"These grants reflect our commitment to supporting India's equitable recovery from COVID-19, and we look forward to working alongside the Government of India to advance this urgent goal," Naveen Rao added.
These grants are part of The Rockefeller Foundation's ongoing COVID-19 response strategy, a global, USD 100 million commitment to improve public health and expand equitable access to testing and contract tracing. To date, the Foundation has dedicated grants to supporting frontline organizations in Africa and Asia, as well as strengthening the United States' domestic response.
Centre for Cellular and Molecular Platforms (C-CAMP) is an initiative of Department of Biotechnology (DBT), Government of India and a member of the Bangalore Life Sciences Cluster (BLiSC), with a mandate to enable cutting-edge life science research and innovation and promote life science entrepreneurship.
It is India's premier innovation and technology hub as well as one of the largest and most thriving life sciences incubators in the country. C-CAMP has directly funded, incubated and mentored close to 150 start-ups over the last few years and is connected to 1000 plus start-ups and entrepreneurs across the country in healthcare, agriculture and environment. C-CAMP is an initiative supported by Department of Biotechnology, Ministry of Science and Technology, AIM-NITI Aayog, Ministry of Electronics and Information Technology (MeitY), GoI, and Government of Karnataka.
PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world's most pressing health challenges. Our team of innovators comprises more than 1,500 employees in offices in 20 countries.
With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions - including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide. We work in more than 70 countries to transform bold ideas into sustainable solutions that improve health and well-being for all, reaching over 150 million people, on average, each year.
The Rockefeller Foundation's mission - unchanged since 1913 - is to promote the well-being of humanity throughout the world. Today the Foundation advances new frontiers of science, policy, and innovation to solve global challenges related to health, food, power, and economic mobility.
As a science-driven philanthropy focused on building collaborative relationships with partners and grantees, The Rockefeller Foundation seeks to inspire and foster large-scale human impact by identifying and accelerating breakthrough solutions, ideas and conversations.
In health, The Rockefeller Foundation has been working to improve global public health for more than a century - from eradicating hookworm in the American South, to launching the field of public health, to seeding the development of the life-saving yellow fever vaccine.
The Foundation's Precision Public Health initiative aims to empower community health systems and frontline health workers with the latest digital innovations - including more accurate and precise decision-making tools based on predictive analytics, artificial intelligence, and machine learning.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)
Disclaimer: The views expressed in the article above are those of the authors' and do not necessarily represent or reflect the views of this publishing house. Unless otherwise noted, the author is writing in his/her personal capacity. They are not intended and should not be thought to represent official ideas, attitudes, or policies of any agency or institution.